Molecular characterization of a patient's small cell carcinoma of the ovary of the hypercalcemic type

Bret Stephens, Stephen P. Anthony, Haiyong Han, Jeffery Kiefer, Galen Hostetter, Michael Barrett, Daniel D. Von Hoff

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Small cell carcinoma of the ovary of the hypercalcemic type (SCCOHT) is a very rare tumor type that mainly affects young women. We report a 21-year old woman with SCCOHT. The patient initially presented with stage T3AN1MX disease and treated with surgery. The patient then received 8 cycles of multi-agent chemotherapy including cisplatin, bleomycin, cyclophosphamide, doxorubicin, and etoposide. Upon relapse, the patient underwent total abdominal hysterectomy, followed by chemotherapy with gemcitabine. The patient subsequently received radiation therapy and chemotherapy with bevacizumab, irinotecan and docetaxel. She passed away approximately 5 months after the second surgery and with her prior permission an immediate autopsy was performed. We examined the gene expression and copy number profiles of the tumor tissue samples obtained from the autopsy and compared them to normal ovary tissues. Our results indicated that although this tumor did not harbor chromosomal abnormalities nor gene copy number changes, there were significant gene expression changes in a number of genes/pathways. More than 5,000 genes showed significant differential expression in the tumor when compared to normal ovary tissue. Pathway enrichment analysis further identified several pathways/processes including the Vitamin D receptor signaling and the hedgehog signaling pathways to be significantly dysregulated. The gene expression profiling also suggests a number of agents such as pazopanib, bortezomib, 5-azacytidine, and PARP inhibitors as treatment options to possibly explore in future trials against this disease.

Original languageEnglish (US)
Pages (from-to)58-66
Number of pages9
JournalJournal of Cancer
Volume3
Issue number1
DOIs
StatePublished - 2012
Externally publishedYes

Fingerprint

Small Cell Carcinoma
Ovary
irinotecan
Gene Dosage
docetaxel
gemcitabine
Drug Therapy
Autopsy
Neoplasms
Gene Expression
Azacitidine
Calcitriol Receptors
Bleomycin
Gene Expression Profiling
Etoposide
Hysterectomy
Chromosome Aberrations
Doxorubicin
Cyclophosphamide
Cisplatin

Keywords

  • Hypercalcemic type
  • Ovarian carcinoma
  • Small cell carcinoma

ASJC Scopus subject areas

  • Oncology

Cite this

Stephens, B., Anthony, S. P., Han, H., Kiefer, J., Hostetter, G., Barrett, M., & Von Hoff, D. D. (2012). Molecular characterization of a patient's small cell carcinoma of the ovary of the hypercalcemic type. Journal of Cancer, 3(1), 58-66. https://doi.org/10.7150/jca.3872

Molecular characterization of a patient's small cell carcinoma of the ovary of the hypercalcemic type. / Stephens, Bret; Anthony, Stephen P.; Han, Haiyong; Kiefer, Jeffery; Hostetter, Galen; Barrett, Michael; Von Hoff, Daniel D.

In: Journal of Cancer, Vol. 3, No. 1, 2012, p. 58-66.

Research output: Contribution to journalArticle

Stephens, B, Anthony, SP, Han, H, Kiefer, J, Hostetter, G, Barrett, M & Von Hoff, DD 2012, 'Molecular characterization of a patient's small cell carcinoma of the ovary of the hypercalcemic type', Journal of Cancer, vol. 3, no. 1, pp. 58-66. https://doi.org/10.7150/jca.3872
Stephens, Bret ; Anthony, Stephen P. ; Han, Haiyong ; Kiefer, Jeffery ; Hostetter, Galen ; Barrett, Michael ; Von Hoff, Daniel D. / Molecular characterization of a patient's small cell carcinoma of the ovary of the hypercalcemic type. In: Journal of Cancer. 2012 ; Vol. 3, No. 1. pp. 58-66.
@article{6e6dc1011d3d452a82e04ae57a22d002,
title = "Molecular characterization of a patient's small cell carcinoma of the ovary of the hypercalcemic type",
abstract = "Small cell carcinoma of the ovary of the hypercalcemic type (SCCOHT) is a very rare tumor type that mainly affects young women. We report a 21-year old woman with SCCOHT. The patient initially presented with stage T3AN1MX disease and treated with surgery. The patient then received 8 cycles of multi-agent chemotherapy including cisplatin, bleomycin, cyclophosphamide, doxorubicin, and etoposide. Upon relapse, the patient underwent total abdominal hysterectomy, followed by chemotherapy with gemcitabine. The patient subsequently received radiation therapy and chemotherapy with bevacizumab, irinotecan and docetaxel. She passed away approximately 5 months after the second surgery and with her prior permission an immediate autopsy was performed. We examined the gene expression and copy number profiles of the tumor tissue samples obtained from the autopsy and compared them to normal ovary tissues. Our results indicated that although this tumor did not harbor chromosomal abnormalities nor gene copy number changes, there were significant gene expression changes in a number of genes/pathways. More than 5,000 genes showed significant differential expression in the tumor when compared to normal ovary tissue. Pathway enrichment analysis further identified several pathways/processes including the Vitamin D receptor signaling and the hedgehog signaling pathways to be significantly dysregulated. The gene expression profiling also suggests a number of agents such as pazopanib, bortezomib, 5-azacytidine, and PARP inhibitors as treatment options to possibly explore in future trials against this disease.",
keywords = "Hypercalcemic type, Ovarian carcinoma, Small cell carcinoma",
author = "Bret Stephens and Anthony, {Stephen P.} and Haiyong Han and Jeffery Kiefer and Galen Hostetter and Michael Barrett and {Von Hoff}, {Daniel D.}",
year = "2012",
doi = "10.7150/jca.3872",
language = "English (US)",
volume = "3",
pages = "58--66",
journal = "Journal of Cancer",
issn = "1837-9664",
publisher = "Ivyspring International Publisher",
number = "1",

}

TY - JOUR

T1 - Molecular characterization of a patient's small cell carcinoma of the ovary of the hypercalcemic type

AU - Stephens, Bret

AU - Anthony, Stephen P.

AU - Han, Haiyong

AU - Kiefer, Jeffery

AU - Hostetter, Galen

AU - Barrett, Michael

AU - Von Hoff, Daniel D.

PY - 2012

Y1 - 2012

N2 - Small cell carcinoma of the ovary of the hypercalcemic type (SCCOHT) is a very rare tumor type that mainly affects young women. We report a 21-year old woman with SCCOHT. The patient initially presented with stage T3AN1MX disease and treated with surgery. The patient then received 8 cycles of multi-agent chemotherapy including cisplatin, bleomycin, cyclophosphamide, doxorubicin, and etoposide. Upon relapse, the patient underwent total abdominal hysterectomy, followed by chemotherapy with gemcitabine. The patient subsequently received radiation therapy and chemotherapy with bevacizumab, irinotecan and docetaxel. She passed away approximately 5 months after the second surgery and with her prior permission an immediate autopsy was performed. We examined the gene expression and copy number profiles of the tumor tissue samples obtained from the autopsy and compared them to normal ovary tissues. Our results indicated that although this tumor did not harbor chromosomal abnormalities nor gene copy number changes, there were significant gene expression changes in a number of genes/pathways. More than 5,000 genes showed significant differential expression in the tumor when compared to normal ovary tissue. Pathway enrichment analysis further identified several pathways/processes including the Vitamin D receptor signaling and the hedgehog signaling pathways to be significantly dysregulated. The gene expression profiling also suggests a number of agents such as pazopanib, bortezomib, 5-azacytidine, and PARP inhibitors as treatment options to possibly explore in future trials against this disease.

AB - Small cell carcinoma of the ovary of the hypercalcemic type (SCCOHT) is a very rare tumor type that mainly affects young women. We report a 21-year old woman with SCCOHT. The patient initially presented with stage T3AN1MX disease and treated with surgery. The patient then received 8 cycles of multi-agent chemotherapy including cisplatin, bleomycin, cyclophosphamide, doxorubicin, and etoposide. Upon relapse, the patient underwent total abdominal hysterectomy, followed by chemotherapy with gemcitabine. The patient subsequently received radiation therapy and chemotherapy with bevacizumab, irinotecan and docetaxel. She passed away approximately 5 months after the second surgery and with her prior permission an immediate autopsy was performed. We examined the gene expression and copy number profiles of the tumor tissue samples obtained from the autopsy and compared them to normal ovary tissues. Our results indicated that although this tumor did not harbor chromosomal abnormalities nor gene copy number changes, there were significant gene expression changes in a number of genes/pathways. More than 5,000 genes showed significant differential expression in the tumor when compared to normal ovary tissue. Pathway enrichment analysis further identified several pathways/processes including the Vitamin D receptor signaling and the hedgehog signaling pathways to be significantly dysregulated. The gene expression profiling also suggests a number of agents such as pazopanib, bortezomib, 5-azacytidine, and PARP inhibitors as treatment options to possibly explore in future trials against this disease.

KW - Hypercalcemic type

KW - Ovarian carcinoma

KW - Small cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84881102373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881102373&partnerID=8YFLogxK

U2 - 10.7150/jca.3872

DO - 10.7150/jca.3872

M3 - Article

C2 - 22315651

AN - SCOPUS:84881102373

VL - 3

SP - 58

EP - 66

JO - Journal of Cancer

JF - Journal of Cancer

SN - 1837-9664

IS - 1

ER -